CytoMed Secures Malaysian Patent for Cancer-Targeting T-Cell Tech
Ticker: GDTC · Form: 6-K · Filed: Jan 29, 2024 · CIK: 1873093
| Field | Detail |
|---|---|
| Company | Cytomed Therapeutics LTD (GDTC) |
| Form Type | 6-K |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: patent-grant, biotechnology, immunotherapy, intellectual-property
TL;DR
**CytoMed just got a key patent in Malaysia for its cancer-fighting T-cell tech, boosting its IP.**
AI Summary
CytoMed Therapeutics Ltd. announced on January 29, 2024, that the Intellectual Property Corporation of Malaysia granted a patent (Application No.: PI2019004561, Grant No.: MY-200528-A) for its allogeneic chimeric antigen receptor gamma delta T cell technology. This patent, titled "Gamma Delta T Cells and a Method of Augmenting the Tumoricidal Activity of the Same," covers methods for expanding gamma delta T cells and modifying them to target a broad spectrum of cancers. This matters to investors because CytoMed holds an exclusive, worldwide license for this technology, potentially enhancing its competitive position and future revenue streams in the immunotherapy market.
Why It Matters
This patent grant strengthens CytoMed's intellectual property portfolio, providing a competitive advantage in the rapidly evolving field of cancer immunotherapy and potentially increasing the long-term value of its stock.
Risk Assessment
Risk Level: low — The filing reports a positive development (patent grant) with no apparent immediate risks or negative implications for the company.
Analyst Insight
A smart investor would view this patent as a positive long-term indicator, reinforcing CytoMed's competitive moat in the immunotherapy space, and might consider it a factor in their investment thesis, though further clinical progress remains crucial.
Key Players & Entities
- CytoMed Therapeutics Ltd. (company) — the registrant and recipient of the patent
- Intellectual Property Corporation of Malaysia (company) — the entity that granted the patent
- PI2019004561 (other) — the patent application number
- MY-200528-A (other) — the patent grant number
- January 29, 2024 (date) — the date the press release was issued and the patent was announced
Forward-Looking Statements
- CytoMed's stock price will see a modest increase due to enhanced investor confidence in its intellectual property. (CytoMed Therapeutics Ltd.) — medium confidence, target: 2024-03-29
- The company will pursue additional patent protections in other key markets for this technology. (CytoMed Therapeutics Ltd.) — high confidence, target: 2025-01-29
FAQ
What specific technology did CytoMed Therapeutics Ltd. receive a patent for?
CytoMed Therapeutics Ltd. received a patent for its exclusively licensed allogeneic chimeric antigen receptor gamma delta T cell (γδ T cells) technology, specifically covering "Gamma Delta T Cells and a Method of Augmenting the Tumoricidal Activity of the Same."
Which country's intellectual property office granted this patent?
The Intellectual Property Corporation of Malaysia granted the patent to CytoMed Therapeutics Ltd.
What are the key capabilities covered by the newly granted patent?
The patent covers technologies for the clinical-scale expansion of γδ T cells from a small amount of donor peripheral blood cells and the modification of these expanded cells to incorporate a chimeric antigen receptor, enabling them to recognize a wide range of cancers, including both solid and hematologic cancers.
What kind of license does CytoMed Therapeutics Ltd. hold for this patented technology?
CytoMed Therapeutics Ltd. holds an exclusive, worldwide license for the use of this technology in immunotherapy, including stem cell therapy, until the patent's expiration.
When was the press release announcing this patent issued?
The press release announcing the patent grant was issued on January 29, 2024.
Filing Stats: 368 words · 1 min read · ~1 pages · Grade level 15.9 · Accepted 2024-01-29 07:00:17
Filing Documents
- form6-k.htm (6-K) — 17KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 40KB
- 0001493152-24-004055.txt ( ) — 89KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CytoMed Therapeutics Limited Date: January 29, 2024 By: /s/ CHOO Chee Kong CHOO Chee Kong Director and Chairman